Genmab A/S
- GMAB
- NASDAQ
- Biotechnology
- Antibody Therapeutics (Cancer)
- Immuno-Oncology
$37.00
Today −2.17%Quote Oct 16, 2026, 08:00 PM UTC
+7.15%over the last month
Max drawdown −6.3%From 1-month high −3.8%3 months +32.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$22.75B
Quote Oct 16
Next earnings
Nov 5
Expected, not confirmed
Analyst target
$44.75
+20.9% from here
Floor
$35.63
3.7% below price
Where the price sits
18 analysts
Analyst range, low to high
$38.00$58.00
- Price $37.00
- Resistance $37.57–$37.95
- Consensus $44.75
The price is right under resistance. Analysts' average target sits about 21% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about GMABPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
3,119
Founded
1999